Drug Discovery World

APRIL 8, 2024

In December 2023, Pfizer announced that it had chosen to donate the rights of its royalties from the sale of Bavencio (avelumab) in the United States to the AACR, as an acknowledgment of the AACR’s dedication to sustained innovation in cancer research and treatment.

DNA 130

DNA Small Molecule Science Treatment 130

Drug Target Review

NOVEMBER 6, 2023

Advances in research and development and the utilisation of combination treatment strategies are revolutionising the haematology care landscape, but more must be done to address patients’ individual needs. 2 It is this complexity that necessitates powerful, targeted combination therapies. References Blood Cancer UK.

Small Molecule 110

Small Molecule Therapies Treatment Immune Response 110

Drug Discovery World

FEBRUARY 22, 2023

More than 20% of new drugs are now coming from small innovative organisations and this percentage is increasing exponentially as these small organisations adopt this new technology. At the same time government agencies will push to supply these treatments at the lowest possible cost, putting increasing pressure on big pharma.

Small Molecule 130

Small Molecule Drug Development Drugs Packaging 130

LifeSciVC

JULY 6, 2023

Although these results cannot prove that there is no possibility of finding a high-affinity small molecule binder of NBD1, they are discouraging…” It turns out the small molecules they were looking for are not only possible – they were ready for a dedicated team to push them ahead.

Small Molecule 48

Small Molecule Licensing Licensing Science 48

Drug Discovery World

APRIL 6, 2023

Science ↔ Survivor Program As mentioned previously, AACR has a Scientist↔Survivor Program. Its purpose is to build enduring partnerships between the leaders of the scientific, cancer survivor, and patient advocacy communities worldwide.

Small Molecule 130

Small Molecule Targeted Protein Degradation Clinical Trials Engineering 130

Drug Discovery World

APRIL 27, 2023

Research spotlight : In February 2023, Duke University co-investigators took a groundbreaking step in the treatment of geographic atrophy (GA), an advanced form of dry macular degeneration through the FDA approval of pegcetacoplan, the first ever FDA-approved treatment for GA.

Small Molecule 130

Small Molecule Science Drugs FDA Approval 130

Drug Target Review

JULY 13, 2023

Drug discovery is a complex and vital field that continually seeks to identify new therapeutic targets and develop effective treatments. They found that although the targets themselves may not be easily druggable due to their disordered nature, their ability to condense can be modulated using small molecules.

Disease 98

Disease Small Molecule Cell Biology Medical Schools 98

Drug Discovery World

JUNE 5, 2023

How best to communicate this strategy to both internal and external stakeholders? New approaches to partnering In this event in the Biotech track, Clive Cookson, Science Editor at the Financial Times, interviewed John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordisk. How to improve its pipeline?

Small Molecule 130

Small Molecule Treatment Science Disease 130

Drug Discovery World

APRIL 10, 2023

However, the role of modern drug discovery technologies and novel treatment approaches is expected to grow over the next few years. The hub offers industrial/knowledge parks, special economic zones (SEZs), multi-tenanted dry and wet laboratories, and incubation facilities, attracting national and international companies.

Vaccine 130

Vaccine Pharmaceuticals Drugs Science 130

The Pharma Data

MAY 15, 2023

Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC and TTM Capital.

Small Molecule 40

Small Molecule DNA Immune Response Science 40

Drug Discovery World

APRIL 25, 2023

Spin-out companies play a vital role in translating Cancer Research UK-funded research from the lab into life-saving treatments. In total, BII’s start-ups have raised over €333 million in external funding from both local and international investors.

Science 130

Science Small Molecule Disease Government 130

The Pharma Data

DECEMBER 15, 2020

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp. NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. BUFFALO, N.Y.,

FDA Approval 52

FDA Approval FDA Treatment Small Molecule 52

The Pharma Data

DECEMBER 21, 2020

Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. The principle of TPD is to use small molecules to commit the target protein into the E3 ligase-mediated degradation pathway thereby eliminating or reducing its activity.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) International 40

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. The university aims to identify treatments for life-threatening anti-microbial diseases and metabolic disorders.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

The Pharma Data

APRIL 28, 2021

OSAKA, Japan, April 28, 2021 – Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it was awarded by the International Society for Pharmaceutical Engineering (ISPE) for the 2021 Facility Of the Year Awards (FOYA) in two categories.

Packaging 52

Packaging Small Molecule Pharmaceutical Companies Engineering 52

New Drug Approvals

JANUARY 31, 2024

INAXAPLIN, 2446816-88-0 2446816-88-0 S2SJ2RVZ6Y UNII-S2SJ2RVZ6Y C 21 H 18 F 3 N 3 O 3 3-[5,7-difluoro-2-(4-fluorophenyl)-1 H -indol-3-yl]- N -[(3 S ,4 R )-4-hydroxy-2-oxopyrrolidin-3-yl]propanamide Inaxaplin ( VX-147 ) is a small-molecule apolipoprotein L1 inhibitor developed by Vertex Pharmaceuticals for APOL1-mediated kidney disease.

International 52

International Disease Small Molecule Production 52

Vial

DECEMBER 11, 2023

Despite advances in clinical research, there remain significant challenges as only 20% of HCV cases are diagnosed, and of these, only 15% receive treatment. The Food and Drug Administration (FDA) approved and recommended dozens of small-molecule drugs. Two highly effective pan-genotypic DAAs are used worldwide.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

The Premier Consulting Blog

JULY 9, 2023

During the development of new small molecule drug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. The TTC varies based on the clinical treatment duration and on whether multiple mutagenic impurities are present.

Small Molecule 52

Small Molecule DNA Drugs Clinical Development 52

The Pharma Data

OCTOBER 15, 2020

a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry.

Targeted Protein Degradation 52

Targeted Protein Degradation Small Molecule Science Disease 52

KIF1A

JUNE 30, 2023

KAND and Spasticity : We created this resource to help families understand mechanisms of spasticity in KAND, including considerations between different treatment options. With your support, KIF1A.ORG continues to bring together the expertise and innovation needed to rapidly discover treatments and cures for KAND.

Small Molecule 52

Small Molecule Treatment Doctors Research 52

The Pharma Data

MAY 16, 2022

About Digestive Disease Week® Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

Disease 40

Disease Small Molecule Treatment Trials 40

Drug Target Review

NOVEMBER 22, 2023

How does iOnctura plan to design novel combination treatments that effectively target both autotaxin and the TGF pathway while ensuring safety for patients? We will present some of the data at the end of the study at an international conference next year. Are there any unique strategies or approaches being considered?

Licensing 52

Licensing Licensing Small Molecule Therapies 52

The Pharma Data

OCTOBER 18, 2020

DUBLIN–( BUSINESS WIRE )– Inflection Biosciences Ltd , a company developing innovative therapeutics for the treatment of cancer, today announced the appointment of industry veteran Gregory I. Inflection Biosciences Ltd is developing small molecule therapeutics for the treatment of cancer. 19, 2020 08:02 UTC.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

MARCH 1, 2022

This acquisition gives AbbVie access to Syndesi’s portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. ” The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. .

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

The Pharma Data

JANUARY 13, 2021

The patent application is titled “Anti-CD154 Antibodies and Uses Thereof” and published under International Publication No. International Immunol. (11):1583 include: infliximab (Remicade®), adalimumab (Humira®), certolizumab pegol (Cimzia®), and golimumab (Simponi®) for the treatment of certain autoimmune conditions. Structure.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

OCTOBER 6, 2021

The companies do not expect the introduction of booster doses in the United States and the EU, if authorized, to impact the existing supply agreements in place with governments and international health organizations around the world.

Vaccine 52

Vaccine Small Molecule Government Therapies 52

The Pharma Data

MARCH 4, 2021

Our goal is to one day bring new treatment options that provide greater seizure control, tolerability and function to DS and LGS patients around the world.”. Advancing New Treatment Options for DS and LGS Patients. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. selective GABA A receptor agonist.

Treatment 52

Treatment Pharmaceutical Companies Clinical Trials Licensing 52

Drug Discovery World

NOVEMBER 17, 2022

“Eons of evolution have given bacteria unique ways of engaging in warfare and killing other bacteria without their foes developing resistance,” said Brady, the Evnin Professor and head of the Laboratory of Genetically Encoded Small Molecules. The research we have carried out paves the way to this type of treatment.” .

Engineering 130

Engineering Molecular Biology Synthetic Chemistry DNA 130

The Pharma Data

NOVEMBER 1, 2020

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company is managed by a team with broad international, commercial and clinical-science experience.

Clinical Pharmacology 52

Clinical Pharmacology Small Molecule Clinical Research Science 52

The Pharma Data

JULY 15, 2021

“Several high impact Victorian healthcare collaborations have been signed since our launch, including those novel medical technologies and treatments for neurodegenerative and autoimmune conditions, and solutions for significant unmet needs in global public health including maternal mortality and infectious diseases.”

Government 52

Government Science Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 29, 2020

1 Meanwhile, these MDM2 inhibitors present some challenges, including dose-limiting hematological toxicities, thus the urgent need to develop new generation of MDM2-targeting therapies in the treatment of cancer. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment.

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40

The Pharma Data

APRIL 22, 2023

While no cure is available for MS, existing disease-modifying therapies in the form of small molecule and protein drugs either directly target the self-reactive immune cells or broadly dampen inflammation. Adding certain molecules to the backpacks allowed the team sustained control over the cells’ behavior.

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

The Pharma Data

NOVEMBER 18, 2020

Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan. Title: OBI-833 was safe and immunogenic, without treatment-related SAEs, in a Phase 1 dose-escalation trial. Session Title: E-poster Display session – Thoracic tumours, metastatic. Session Date and Time: Friday, November 20, 2020.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

Drug Discovery World

MARCH 11, 2024

Galimedix Therapeutics has announced data showing small molecule GAL-201 has neuroprotective and symptomatic alleviation potential in models of Alzheimer’s disease (AD). These new findings support previous studies where GAL-201 was characterised as a promising development candidate for the treatment of AD (Russ et.

Small Molecule 130

Small Molecule Drugs International Disease 130

The Pharma Data

JANUARY 7, 2021

NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of Dr. Anne Prener to its Board of Directors. “We BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) — Galecto, Inc., We warmly welcome Anne to our Board.

Small Molecule 52

Small Molecule Clinical Development Production Science 52

The Pharma Data

NOVEMBER 22, 2020

Omecamtiv mecarbil is an investigational cardiac myosin activator, developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF), and was recently studied in GALACTIC-HF, a positive Phase 3 cardiovascular outcomes clinical trial. After a median duration of follow-up of 21.8

Clinical Trials 52

Clinical Trials Licensing Licensing Trials 52

The Pharma Data

DECEMBER 17, 2020

Most recently, Cadavid served as senior vice president and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases. AB2 Bio – Swiss pharma company AB2 Bio Ltd. named Djordje Filipovic as its new chief commercial officer.

Small Molecule 52

Small Molecule Engineering Pharmaceuticals Clinical Development 52